On November 9, Eli Lilly rose 3.01% in Regular Trading, trading at $1392.42/share, with turnover of $573 million.
The main catalyst in publicly available information is the company’s recently announced agreement with Hims & Hers Health to expand patient access to Zepbound and Foundayo. Under the arrangement, eligible patients prescribed by licensed providers on the Hims platform can complete consultations, obtain prescriptions, and order delivery without leaving the platform, while accessing the same self-pay pricing available to other cash-pay patients.
The development is notable because it broadens Eli Lilly’s reach into the self-pay obesity market through a large telehealth channel. It also follows a strong third-quarter report released on October 29, when the company posted revenue of $24.4 billion, up 39% year over year, adjusted EPS of $7.48, and raised full-year revenue guidance to $91 billion-$92 billion, reinforcing investor focus on its obesity and diabetes franchise.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments